Stock News

Analysts See $-0.79 EPS for Achaogen, Inc. (AKAO); Allianzgi Convertible & Income Fund (NCV) Has 0.65 Sentiment

The stock decreased 2.00% or $0.14 during the last trading session, reaching $6.86. About 389,773 shares traded. AllianzGI Convertible & Income Fund (NCV) has risen 19.58% since February 8, 2017 and is uptrending. It has outperformed by 2.88% the S&P500.

Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to report $-0.79 EPS on March, 13.They anticipate $0.25 EPS change or 24.04% from last quarter’s $-1.04 EPS. After having $-0.85 EPS previously, Achaogen, Inc.’s analysts see -7.06% EPS growth. The stock decreased 1.46% or $0.16 during the last trading session, reaching $10.95. About 561,776 shares traded. Achaogen, Inc. (NASDAQ:AKAO) has risen 757.99% since February 8, 2017 and is uptrending. It has outperformed by 741.29% the S&P500.

Since September 26, 2017, it had 2 buys, and 2 insider sales for $1.72 million activity. Another trade for 1,146 shares valued at $18,325 was made by LOEB GARY on Tuesday, September 26. Another trade for 95,012 shares valued at $1.06 million was bought by DUGGAN ROBERT W. Wise Blake sold 3,576 shares worth $57,180.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $464.12 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Investors sentiment decreased to 1.16 in 2017 Q3. Its down 1.22, from 2.38 in 2017Q2. It worsened, as 23 investors sold Achaogen, Inc. shares while 20 reduced holdings. 14 funds opened positions while 36 raised stakes. 31.77 million shares or 0.83% less from 32.03 million shares in 2017Q2 were reported. Moreover, Fmr Ltd Co has 0.01% invested in Achaogen, Inc. (NASDAQ:AKAO) for 5.06 million shares. Ballentine Ptnrs Ltd owns 19,823 shares for 0.02% of their portfolio. Baker Bros Advisors L P accumulated 3.89M shares. Point72 Asset Mngmt Ltd Partnership holds 2.26 million shares or 0.16% of its portfolio. Reilly Advsr Ltd Liability Corporation invested in 100 shares. Weiss Multi invested 0.02% in Achaogen, Inc. (NASDAQ:AKAO). Voya Inv Mgmt Ltd Llc has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). State Board Of Administration Of Florida Retirement System reported 16,486 shares or 0% of all its holdings. 80,584 are held by Axa. Royal Bancorporation Of Canada owns 0% invested in Achaogen, Inc. (NASDAQ:AKAO) for 3,491 shares. Nea has invested 2.91% in Achaogen, Inc. (NASDAQ:AKAO). Moreover, Perceptive Advisors Ltd Co has 0.02% invested in Achaogen, Inc. (NASDAQ:AKAO). Hamilton Lane Advisors Limited Co reported 11,428 shares. Great West Life Assurance Company Can holds 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 2,200 shares. Hartwell J M Ltd Partnership accumulated 14,000 shares.

Among 10 analysts covering Achaogen (NASDAQ:AKAO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Achaogen had 21 analyst reports since March 16, 2016 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Friday, September 15. Needham upgraded it to “Buy” rating and $19 target in Tuesday, December 13 report. The firm earned “Outperform” rating on Wednesday, January 4 by Leerink Swann. As per Thursday, March 31, the company rating was downgraded by Cowen & Co. Cowen & Co maintained Achaogen, Inc. (NASDAQ:AKAO) on Thursday, June 1 with “Buy” rating. Stifel Nicolaus maintained the shares of AKAO in report on Thursday, August 3 with “Buy” rating. Wedbush maintained Achaogen, Inc. (NASDAQ:AKAO) rating on Wednesday, February 1. Wedbush has “Outperform” rating and $23 target. The stock of Achaogen, Inc. (NASDAQ:AKAO) earned “Buy” rating by Stifel Nicolaus on Tuesday, July 25. The company was initiated on Wednesday, November 2 by Aegis Capital. The firm has “Outperform” rating by Leerink Swann given on Monday, October 9.

E&G Advisors Lp holds 0.52% of its portfolio in AllianzGI Convertible & Income Fund for 163,272 shares. Vident Investment Advisory Llc owns 319,894 shares or 0.12% of their US portfolio. Moreover, Capital Investment Advisors Llc has 0.07% invested in the company for 136,722 shares. The California-based National Planning Corp has invested 0.07% in the stock. Next Financial Group Inc, a Texas-based fund reported 24,140 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *